A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)
Abstract Dostarlimab is a humanized anti–PD-1 monoclonal antibody. Dostarlimab (JEMPERLI; TSR-042) was recently approved in the USA and in the EU. The presence of neutralizing antibodies (NAbs) is a cause for concern because they block the therapeutic function of the antibody and reduce drug efficac...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
SpringerOpen
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/9cc562b825a24dee8a7fce5d389aa00c |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Soyez le premier à ajouter un commentaire!